Protocol for the China PEACE (Patient-centered Evaluative Assessment of Cardiac Events) Million Persons Project pilot

Jiapeng Lu, Si Xuan, Nicholas S Downing, Chaoqun Wu, Li Li, Harlan M Krumholz, Lixin Jiang, Jiapeng Lu, Si Xuan, Nicholas S Downing, Chaoqun Wu, Li Li, Harlan M Krumholz, Lixin Jiang

Abstract

Introduction: Collection of high-quality data from large populations is considered essential to generate knowledge that is critical to an era of precision medicine. Cardiovascular disease (CVD) is a leading cause of mortality in China and is a suitable focus of an initiative to discover factors that would improve our ability to assess and modify individual risk.

Methods and analysis: The pilot phase of China PEACE (Patient-centered Evaluative Assessment of Cardiac Events) Million Persons Project is being conducted during 2014-2015 in four provinces across China to demonstrate the feasibility of a population-based assessment. It is designed to screen 0.4 million community-dwelling residents aged 40-75 years with measurements of blood pressure, height and weight, a lipid blood test, and a questionnaire on cardiovascular-related health status. Participants identified at high risk of CVD receive further health assessments, including ECG, ultrasound scan, blood and urine analysis, and a questionnaire on lifestyle and medical history. Collection of blood and urine samples is used to establish a biobank. High-risk subjects are also counselled with suggestions regarding potential lifestyle changes. In addition, high-risk subjects are followed-up either in a return clinic visit or by telephone interview, with measurement of blood pressure, weight, ECG, and a questionnaire on survival status, hospitalisations and lifestyle. The first 0.1 million participants screened were used to conduct a preliminary analysis, with information on baseline characteristics, health-related behaviours, anthropometric variables, medical history, and prevalence of high-risk subjects.

Ethics and dissemination: The central ethics committee at the China National Center for Cardiovascular Disease (NCCD) approved the pilot. Written informed consent is obtained from all participants on entry into the project. Findings will be disseminated in future peer-reviewed papers and will inform strategies aimed at developing precise methods of assessing and modifying risk.

Trial registration number: NCT02536456.

Keywords: China; cardiovascular disease; counseling; follow-up; population-based project; screening.

Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/

Figures

Figure 1
Figure 1
Geographic distribution of pilot sites. The pilot sites are located in 20 geographically defined regions from four provinces (Jilin, Liaoning, Zhejiang, Guangxi) in China. The 20 local regions consist of 11 urban districts and 9 rural counties.
Figure 2
Figure 2
Criteria for identification of high-risk subjects.

References

    1. National Research Council. Toward precision medicine: building a knowledge network for biomedical research and a new taxonomy of disease. Washington DC: National Academies Press, 2011.
    1. Bi Y, Jiang Y, He J et al. . Status of cardiovascular health in Chinese adults. J Am Coll Cardiol 2015;65:1013–25. 10.1016/j.jacc.2014.12.044
    1. He J, Gu D, Chen J et al. . Premature deaths attributable to blood pressure in China: a prospective cohort study. Lancet 2009;374:1765–72. 10.1016/S0140-6736(09)61199-5
    1. Odegaard AO, Koh WP, Yuan JM et al. . Western-style fast food intake and cardiometabolic risk in an Eastern country. Circulation 2012;126:182–8. 10.1161/CIRCULATIONAHA.111.084004
    1. He J, Gu D, Wu X et al. . Major causes of death among men and women in China. N Engl J Med 2005;353:1124–34. 10.1056/NEJMsa050467
    1. Popkin BM. Synthesis and implications: China's nutrition transition in the context of changes across other low- and middle-income countries. Obes Rev 2014;15(Suppl 1):60–7. 10.1111/obr.12120
    1. Wang X-Q, Chen P-J. Population ageing challenges health care in China. Lancet 2014;383:870 10.1016/S0140-6736(14)60443-8
    1. Moran A, Gu D, Zhao D et al. . Future cardiovascular disease in China: Markov model and risk factor scenario projections from the coronary heart disease policy model-china. Circ Cardiovasc Qual Outcomes 2010;3:243–52. 10.1161/CIRCOUTCOMES.109.910711
    1. Wang S, Marquez P, Langenbrunner J. Toward a healthy and harmonious life in China: stemming the rising tide of non-communicable diseases. Washington: The World Bank, 2011.
    1. Eckel RH, Jakicic JM, Ard JD et al. . 2013 AHA/ACC guideline on lifestyle management to reduce cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines. Circulation 2014;129(25_Suppl_2):S76–99. 10.1161/01.cir.0000437740.48606.d1
    1. Chinese Society of Cardiology of Chinese Medical Association, Editorial Board of Chinese Journal of Cardiology. [Chinese guidelines for prevention of cardiovascular diseases]. Zhonghua Xin Xue Guan Bing Za Zhi 2011;39:3–22.
    1. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383–9.
    1. Sacks FM, Pfeffer MA, Moye LA et al. . The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996;335:1001–9. 10.1056/NEJM199610033351401
    1. Tonkin A, Aylward P, Colquhoun D et al. . Prevention of cardiovascular events and death with Pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998;339:1349–57. 10.1056/NEJM199811053391902
    1. Baigent C, Keech A, Kearney PM et al. , Cholesterol Treatment Trialists’ (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005;366:1267–78. 10.1016/S0140-6736(05)67394-1
    1. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2000;283:1967–75. 10.1001/jama.283.15.1967
    1. Psaty BM, Lumley T, Furberg CD et al. . Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis. JAMA 2003;289:2534–44. 10.1001/jama.289.19.2534
    1. Clair C, Rigotti NA, Porneala B et al. . Association of smoking cessation and weight change with cardiovascular disease among adults with and without diabetes. JAMA 2013;309:1014–21. 10.1001/jama.2013.1644
    1. Kodama S, Tanaka S, Heianza Y et al. . Association between physical activity and risk of all-cause mortality and cardiovascular disease in patients with diabetes: a meta-analysis. Diabetes Care 2013;36:471–9. 10.2337/dc12-0783
    1. Shortreed SM, Peeters A, Forbes AB. Estimating the effect of long-term physical activity on cardiovascular disease and mortality: evidence from the Framingham Heart Study. Heart 2013;99:649–54. 10.1136/heartjnl-2012-303461
    1. Cook NR, Cutler JA, Obarzanek E et al. . Long term effects of dietary sodium reduction on cardiovascular disease outcomes: observational follow-up of the trials of hypertension prevention (TOHP). BMJ 2007;334:885–8. 10.1136/bmj.39147.604896.55
    1. Yu-Poth S, Zhao G, Etherton T et al. . Effects of the National Cholesterol Education Program's Step I and Step II dietary intervention programs on cardiovascular disease risk factors: a meta-analysis. Am J Clin Nutr 1999;69:632–46.
    1. Ness AR, Powles JW. Fruit and vegetables, and cardiovascular disease: a review. Int J Epidemiol 1997;26:1–13. 10.1093/ije/26.1.1
    1. Berger JS, Jordan CO, Lloyd-Jones D et al. . Screening for cardiovascular risk in asymptomatic patients. J Am Coll Cardiol 2010;55:1169–77. 10.1016/j.jacc.2009.09.066
    1. American College of Cardiology. Matching the intensity of risk factor management with the hazard for coronary disease events. J Am Coll Cardiol 1995;96:957–1047.
    1. Greenland P, Alpert JS, Beller GA et al. . 2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2010;122:e584–636. 10.1161/CIR.0b013e3182051b4c
    1. Xu Y, Wang L, He J et al. . Prevalence and control of diabetes in Chinese adults. JAMA 2013;310:948–59. 10.1001/jama.2013.168118
    1. Wang S, Xu L, Jonas JB et al. . Prevalence and associated factors of dyslipidemia in the adult Chinese population. PLoS ONE 2011;6:e17326 10.1371/journal.pone.0017326
    1. Wang H, Zhang X, Zhang J et al. . Factors associated with prevalence, awareness, treatment and control of hypertension among adults in Southern China: a community-based, cross-sectional survey. PLoS ONE 2013;8:e62469 10.1371/journal.pone.0062469
    1. Wei X, Zou G, Yin J et al. . Characteristics of high risk people with cardiovascular disease in Chinese rural areas: clinical indictors, disease patterns and drug treatment. PLoS ONE 2013;8:e54169 10.1371/journal.pone.0054169
    1. Dharmarajan K, Li J, Li X et al. . The China Patient-Centered Evaluative Assessment of Cardiac Events (China PEACE) retrospective study of acute myocardial infarction: study design. Circ Cardiovasc Qual Outcomes 2013;6:732–40. 10.1161/CIRCOUTCOMES.113.000441
    1. Li J, Dharmarajan K, Li X et al. . Protocol for the China PEACE (Patient-centered Evaluative Assessment of Cardiac Events) retrospective study of coronary catheterisation and percutaneous coronary intervention. BMJ Open 2014;4:e004595 10.1136/bmjopen-2013-004595
    1. Collins FS, Varmus H. A new initiative on precision medicine. N Engl J Med 2015;372:793–5. 10.1056/NEJMp1500523
    1. World Health Organization. Prevention of cardiovascular disease. Guidelines for assessment and management of cardiovascular risk. Geneva: WHO, 2007.
    1. World Health Organization/International Society of Hypertension. WHO/ISH Risk prediction charts for 14 WHO epidemiological sub-regions. Geneva: WHO, 2007.
    1. Bidgood WD, Horii SC, Prior FW et al. . Understanding and using DICOM, the data interchange standard for biomedical imaging. J Am Med Inform Assoc 1997;4:199–212. 10.1136/jamia.1997.0040199
    1. Chen Z, Chen J, Collins R et al. . China Kadoorie Biobank of 0.5 million people: survey methods, baseline characteristics and long-term follow-up. Int J Epidemiol 2011;40: 1652–66. 10.1093/ije/dyr120
    1. Li Q, Babor TF, Hao W et al. . The Chinese translations of Alcohol Use Disorders Identification Test (AUDIT) in China: a systematic review. Alcohol Alcohol 2011;46:416–23. 10.1093/alcalc/agr012
    1. Zhao Y, Strauss J, Yang G et al. . China Health and Retirement Longitudinal Study—2011–2012 national baseline users’ guide. Beijing: National School of Development, Peking University, 2013.
    1. Wang HM, Patrick DL, Edwards TC et al. . Validation of the EQ-5D in a general population sample in urban China. Qual Life Res 2012;21:155–60. 10.1007/s11136-011-9915-6
    1. Strauss J, Lei X, Park A et al. . Health outcomes and socio-economic status among the elderly in Gansu and Zhejiang Provinces, China: evidence from the CHARLS pilot. J Popul Ageing 2010;3:111–42. 10.1007/s12062-011-9033-9
    1. Yang ZJ, Liu J, Ge JP et al. . Prevalence of cardiovascular disease risk factor in the Chinese population: the 2007–2008 China National Diabetes and Metabolic Disorders Study. Eur Heart J 2012;33:213–20. 10.1093/eurheartj/ehr205
    1. Gu D, Gupta A, Muntner P et al. . Prevalence of cardiovascular disease risk factor clustering among the adult population of China: results from the International Collaborative Study of Cardiovascular Disease in Asia (InterAsia). Circulation 2005;112:658–65. 10.1161/CIRCULATIONAHA.104.515072
    1. Wang Y, Mi J, Shan XY et al. . Is China facing an obesity epidemic and the consequences? The trends in obesity and chronic disease in China. Int J Obes (Lond) 2007;31:177–88. 10.1038/sj.ijo.0803354
    1. Wu Y, Huxley R, Li L et al. . Prevalence, awareness, treatment, and control of hypertension in China: data from the China National Nutrition and Health Survey 2002. Circulation 2008;118:2679–86. 10.1161/CIRCULATIONAHA.108.788166
    1. Yang G, Fan L, Tan J et al. . Smoking in China: findings of the 1996 National Prevalence Survey. JAMA 1999;282:1247–53. 10.1001/jama.282.13.1247
    1. Flegal KM, Carroll MD, Kit BK et al. . Prevalence of obesity and trends in the distribution of body mass index among US adults, 1999–2010. JAMA 2012;307:491–7. 10.1001/jama.2012.39
    1. Egan BM, Zhao Y, Axon RN. US trends in prevalence, awareness, treatment, and control of hypertension, 1988–2008. JAMA 2010;303:2043–50. 10.1001/jama.2010.650
    1. Manolio TA, Weis BK, Cowie CC et al. . New models for large prospective studies: is there a better way? Am J Epidemiol 2012;175:859–66. 10.1093/aje/kwr453
    1. Leitsalu L, Haller T, Esko T et al. . Cohort profile: Estonian Biobank of the Estonian Genome Center, University of Tartu. Int J Epidemiol 2015;44:1137–47. 10.1093/ije/dyt268

Source: PubMed

Sponsors en medewerkers

Medische omstandigheden

Geneesmiddelinterventies

3
Abonneren